financetom
Business
financetom
/
Business
/
Okta Insider Sold Shares Worth $19,180,332, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Okta Insider Sold Shares Worth $19,180,332, According to a Recent SEC Filing
Dec 26, 2024 2:23 PM

05:08 PM EST, 12/26/2024 (MT Newswires) -- Todd McKinnon, Director, Chief Executive Officer, on December 20, 2024, sold 233,028 shares in Okta ( OKTA ) for $19,180,332.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1660134/000166013424000177/xslF345X05/wk-form4_1735250609.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Jul 23, 2025
Abivax SA ( ABVX ) stock is skyrocketing on Wednesday after the clinical-stage biotechnology company announced overwhelmingly positive topline results from its Phase 3 ABTECT-1 (Study 105) and ABTECT-2 (Study 106) 8-week induction trials for oral obefazimod (ABX464) in adult patients with moderately to severely active ulcerative colitis. The Paris-based company achieved a significant breakthrough with its experimental treatment, which...
Castle Biosciences Says FDA Granted Breakthrough Device Designation to Skin Cancer Test; Shares Up Pre-Bell
Castle Biosciences Says FDA Granted Breakthrough Device Designation to Skin Cancer Test; Shares Up Pre-Bell
Jul 23, 2025
07:31 AM EDT, 07/23/2025 (MT Newswires) -- Castle Biosciences ( CSTL ) said Wednesday the US Food and Drug Administration has granted breakthrough device designation for the company's DecisionDx-Melanoma test. DecisionDx-Melanoma is a gene expression profile test that provides results to guide risk-aligned management decisions for patients diagnosed with stage I to III cutaneous melanoma, a type of skin cancer....
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Healthcare Services Q2 Loss Widens, Revenue Rises
Healthcare Services Q2 Loss Widens, Revenue Rises
Jul 23, 2025
07:34 AM EDT, 07/23/2025 (MT Newswires) -- Healthcare Services Group ( HCSG ) reported a Q2 loss Wednesday of $0.44 per diluted share, wider than a loss of $0.02 a year earlier. Two analysts surveyed by FactSet expected earnings of $0.21 per share. Revenue for the three months ended June 30 was $458.5 million, up from $426.3 million last year....
Copyright 2023-2026 - www.financetom.com All Rights Reserved